Advertisement


Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Advertisement